Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 617.5% from a year ago
Total assets stood at $10.87M at the end of Q1 FY2026, up 617.5% from a year earlier and down 14.7% from the prior quarter. Over 3 fiscal years it compounded at +31.8% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +617.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 12.73M USD
- Year-over-year change
- +1011.6%
- 4-year CAGR
- +25.7%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.73M | +1011.6% |
| FY2024 | 2024-12-31 | 1.15M | -73.4% |
| FY2023 | 2023-12-31 | 4.31M | -22.5% |
| FY2022 | 2022-12-31 | 5.56M | +9.2% |
| FY2021 | 2021-12-31 | 5.09M | — |
Total Assets vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 total assets of $10.87M is the lowest of the 2 companies compared; the peer median is $30.86M.
- Its year-over-year change of +617.5% is the highest of 2, against a peer median of +147.5%.
- Over three fiscal years its annual growth of +31.8% compares with a peer median of +9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $30.86M | +147.5% | +9.7% | |
| Mar 2026 | $10.87M | +617.5% | +31.8% | |
| Peer median (excluding LIXT) | $30.86M | +147.5% | +9.7% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.